This site is intended for healthcare professionals
Industry news

Horizon Pharma plc to acquire DepoMed Inc. for $3 billion

Read time: 1 mins
Last updated:9th Jul 2015
Published:9th Jul 2015
Source: Pharmawand
Horizon Pharma plc announced a proposal to acquire all outstanding shares of Depomed, Inc. for approximately $3.0 billion. DepoMed products in the USA include Nucynta ER for pain control, Cambria for migraine, PecFent for cancer pain and the company holds world rights for Gralise and Zipsor for pain control as well as non-North American rights for Glumetza for diabetes. This is a contested bid.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.